CLINICAL TRIAL: ADV HEAD & NECK CANCER AND OGF

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 晚期头颈部鳞状细胞癌(HNSCC)患者由于肿瘤负担和并存条件而难以治疗。在过去的30年里，这群不幸的患者的总体存活率并没有显著提高。临床前研究表明，阿片生长因子(OGF)及其受体OGFr形成一个张力活性的生长抑制系统，以HNSCC的细胞复制为靶点。对不能切除的胰腺癌患者进行的I期研究取得了一定的效果。OGF在人体内的安全性和最大耐受量已经确定，并已得到FDA的批准。 本研究的目的是确定OGF-OGFr轴治疗50例晚期HNSCC患者的生存和生活质量的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with advanced head and neck squamous cell cancer HNSCC) are difficult to treat due to their tumor burden and co-morbid conditions. Overall survival for this unfortunate group of patients has not improved, significantly, in the past 30 years. Preclinical studies have demonstrated that opiod growth factor (OGF) and its receptor, OGFr, form a tonically active growth inhibitory system that targets cell replication in HNSCC. Phase I studies in patients with unresectable pancreatic cancer has been somewhat efficacious. The safety and maximum tolerated dose of OGF, in humans, has been established and it has been approved by the FDA. The objective of this study is to determine the efficacy of the OGF-OGFr axis in the treatment of 50 patients with advanced HNSCC in terms of survival and quality of life.